ACC 2021 | LAAOS III: Appendage Closure During Central Vascular Surgery

According to the LAAOS III study, presented at the American College of Cardiology (ACC) 2021 Congress and simultaneously published in the New England Journal of Medicine (NEJM), patients with atrial fibrillation who undergo central vascular surgery for any other indication find benefit in appendage closure during said surgery.

ACC 2021 | LAAOS III: Cierre de orejuela durante una cirugía vascular central

Using oral anticoagulation agents, patients undergoing appendage closure had a rate of stroke and systemic embolism of 4.8% vs. 7% for patients whose appendages were left untouched. This difference is highly significant (hazard ratio [HR]: 0.67; 95% confidence interval [CI]: 0.53-0.85).

This work provides definite information about the benefits of appendage closure in terms of stroke in patients with atrial fibrillation. The benefit is even greater if the peri-operative period is excluded.

Current American and European guidelines provide a class 2B recommendation to appendage closure during surgery. These new data is bound to change this recommendation.

The LAAOS III study was conducted in 105 centers in 27 countries and was designed to provide definite information on the topic—which it ultimately did.

After randomizing 5000 patients, the safety committee recommended interrupting the study due to the clear benefit observed in the active arm.


Read also: ACC 2021 | Stress Increases Events in Young Patients with Prior MI.


All included patients had atrial fibrillation, a CHA2DS2-VASc score ≥2, and an indication for cardiac surgery.

About two thirds of patients underwent valvular surgery and 20% had isolated myocardial revascularization surgery. 

Up to 30% of patients had prior ablation resulting from their atrial fibrillation. Pump time (119 vs. 113 min) and clamp duration (86 vs. 82 min; p < 0.001) were significantly longer in the active arm, but accounted for only five extra minutes, which were worth it.


Read also: Is Rheumatic Etiology Counter Indicated for TAVR?


While all techniques for appendage surgical closure were allowed in the protocol, the most used were amputation and suture closure of the stump.

Closure significantly reduced the chance of stroke and systemic embolism at 3.8 years of follow-up, driven by a lower chance of stroke (4.2% vs. 6.6%; HR: 0.62; 95% CI: 0.48 to 0.80). The curves began to separate a few days after surgery and were completely divergent after 30 days.

cierre-orejuela-laaos

Original Title: Left atrial appendage occlusion during cardiac surgery to prevent stroke.

Reference: R.P. Whitlock et al. Presentado en el ACC 2021 y publicado simultáneamente en NEJM. DOI: 10.1056/NEJMoa2101897.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

ACC 2025 | BHF PROTECT-TAVI: Are Cerebral Protection Systems Necessary in TAVI?

TAVI has seen a steady increase in use, though stroke continues to be one of its unwanted complications, mostly ischemic and, less frequently, hemorrhagic. The...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...